
## **Mark Shackleton**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6067773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficient tumour formation by single human melanoma cells. Nature, 2008, 456, 593-598.	27.8	1,674
2	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	27.8	1,206
3	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
4	Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized. Cancer Cell, 2010, 18, 510-523.	16.8	555
5	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.9	270
6	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling, 2015, 8, ra82.	3.6	114
7	Human Melanoma Metastasis in NSG Mice Correlates with Clinical Outcome in Patients. Science Translational Medicine, 2012, 4, 159ra149.	12.4	98
8	Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics, 2014, 30, 1064-1072.	4.1	75
9	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
10	The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene, 2020, 39, 5267-5281.	5.9	53
11	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-14.	3.0	51
12	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications, 2021, 12, 1434.	12.8	46
13	Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications, 2016, 7, 12336.	12.8	43
14	Somatic Hypermutation of the <i>YAP</i> Oncogene in a Human Cutaneous Melanoma. Molecular Cancer Research, 2019, 17, 1435-1449.	3.4	39
15	Bevacizumab as a steroidâ€ <del>s</del> paring agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports, 2019, 2, e115.	1.5	29
16	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research, 2016, 76, 3965-3977.	0.9	26
17	Postâ€operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of preâ€operative treatment and elective indication. Journal of Surgical Oncology, 2015, 111, 980-984.	1.7	24
18	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer, 2021, 22, e425-e430.	2.6	15

MARK SHACKLETON

#	Article	IF	CITATIONS
19	Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review. BMJ Open, 2021, 11, e040751.	1.9	13
20	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, 150-156.	0.8	11
21	Reduced melanoma referrals during COVID-19 lockdown. Australian Journal of General Practice, 2021, 50, .	0.8	6
22	Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clinical and Translational Radiation Oncology, 2021, 30, 95-99.	1.7	5
23	Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice. Breast Cancer Research and Treatment, 2020, 183, 565-575.	2.5	4
24	Personalised surveillance after treatment for high-risk cancer. Oncotarget, 2019, 10, 694-695.	1.8	2
25	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry ( <scp>MelCOR</scp> ): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.7	2
26	Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs. Cell Death and Disease, 2022, 13, 301.	6.3	1